GlassScriptPhysician profile
Kudagal S Murthy
NPI 1255384103
$3,147.12
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $583 · 2021: $816 · 2022: $931 · 2023: $359 · 2024: $77.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $436.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $478.37 | 2019-2023 | Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $460.55 | 2019-2023 | Nucala |
| Csl Behring | $442.94 | 2019-2024 | Hizentra, Haegarda, Privigen |
| Kaleo, INC. | $237.15 | 2019-2022 | |
| Biocryst US Sales Co., LLC | $209.62 | 2021-2023 | Orladeyo |
| Pfizer INC. | $169.03 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $137.36 | 2020-2023 | Airduo Digihaler |
| Genzyme Corporation | $124.83 | 2020-2023 | |
| Amgen INC. | $103.78 | 2021-2023 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.93 | 2020-2022 | |
| Pharming Healthcare, INC. | $81.11 | 2022-2024 | Ruconest |
| Optinose US, INC. | $73.72 | 2020-2021 | |
| Octapharma USA, INC. | $69.33 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.68 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $63.38 | 2020-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covis Pharma Gmbh | $61.72 | 2021 | |
| Grifols USA, LLC | $57.21 | 2020-2021 | |
| Incyte Corporation | $55.12 | 2023 | Opzelura |
| Circassia INC. | $51.39 | 2019-2021 | |
| Aerin Medical INC. | $39.44 | 2022 | |
| Novartis Pharmaceuticals Corporation | $31.22 | 2019 | |
| Horizon Therapeutics Plc | $20.03 | 2019 | |
| Genentech USA, INC. | $13.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kudagal Murthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.